GCJ904

GCJ904 is a small molecule inhibitor targeting the **KRAS G12C** mutation, currently in early-stage clinical development for the treatment of advanced solid tumors. Developed by **Hefei China Resources Novartis Pharmaceutical** (a joint venture between **Novartis** and **China Resources Pharmaceutical Group**), the drug is designed to address malignancies driven by the G12C substitution in the KRAS protein, a common oncogenic driver in non-small cell lung cancer (NSCLC), colorectal cancer, and other solid tumors. GCJ904 functions by covalently binding to the cysteine residue of the mutant KRAS protein, effectively inhibiting the MAPK/ERK signaling pathway and suppressing tumor cell proliferation. It is currently being evaluated in Phase 1 clinical trials (e.g., CTR20233346) to assess its safety, tolerability, and preliminary efficacy in patients with KRAS G12C-mutated cancers.